Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dimethyltryptamine + harmine
- Development stage
- Unknown
- Lead developer
- Psychiatrische Universitätsklinik Zürich
- Modality
- Small Molecules
- Administration
- Oral, Intranasal
01
Overview
Dimethyltryptamine (DMT) + harmine is an ayahuasca-inspired combination therapy being investigated by the Psychiatric University Hospital, Zurich for the treatment of depressive disorder and anxiety. The formulation consists of harmine, a reversible inhibitor of monoamine oxidase A (RIMA), administered as an orodispersible tablet, and N,N-dimethyltryptamine (DMT), a serotonergic psychedelic, administered intranasally. Harmine serves to inhibit the metabolic breakdown of DMT by monoamine oxidase, thereby extending its duration of action and potentially enhancing its therapeutic efficacy. DMT primarily acts as an agonist at the 5-HT2A serotonin receptor, inducing profound changes in perception, neurodynamics, and emotional processing. This combination is intended to facilitate psychological insights and emotional breakthroughs with lasting positive effects on prosociality and mental health.
- Other names
- N,N-dimethyltryptamine + harmineDMT + harmineAyahuasca-inspired formulation
02
Targets
HTR2A (Serotonin receptor 5-HT2A)MAOA (Monoamine oxidase A)
Beyond the preview
Go deeper on dimethyltryptamine + harmine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dimethyltryptamine + harmine.